Navigation Links
Cell Therapeutics Reports Second Quarter 2013 Financial Results
Date:7/31/2013

omparator therapies assigned by the G-BA under Germany's AMNOG law.  The determination reflected the absence of a comparator under AMNOG law specifically for this stage of aggressive NHL because prior to the approval of PIXUVRI in the European Union (E.U.), there was no therapy specifically approved for this stage of disease. The G-BA also decided that the prescribability for PIXUVRI should be limited to hematologists and oncologists. CTI is currently negotiating pricing with the GKV-SV, the Federal Association of Statutory Health Insurance Funds.

Research and Development:  New Data Presentation on Pacritinib's Safety Profile

  • Reported results from pooled integrated safety analysis from four Phase 1 and 2 clinical studies that demonstrated the safety, tolerability and persistence of pacritinib, CTI's novel, oral JAK2/FLT3 inhibitor, in patients with myelofibrosis at the European Hematology Association Congress.
  • Reported on the publication of a comprehensive article summarizing preclinical and clinical data for pacritinib, authored by Srdan Verstovsek, M.D., Ph.D., et al., in the journal Drugs of the Future 2013.
  • Corporate:  Added to Russell Indices and Established Leadership for SAB

  • Added to Russell Investments' Russell 3000® and Russell Global indices.
  • Named distinguished cancer investigator, Daniel Von Hoff, M.D., F.A.C.P., as Chairman and to lead formation of CTI's Scientific Advisory Board (SAB).
  • Second Quarter 2013 Financial ResultsTotal revenues for the second quarter and the six months ended June 30, 2013 were $0.3 million and $1.4 million, respectively.  The revenues were solely attributable to net product sales of PIXUVRI.  CTI sells PIXUVRI directly to health care providers and through a limited number of wholesale distributors in the E.U.  CTI records product sales upon receipt of the product by the health care provider or distributor, n
    '/>"/>

    SOURCE Cell Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
    2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
    3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
    7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
    8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
    9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
    10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
    11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
    (Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
    (Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
    Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
    ...   , Strategic collaboration with Ipsen for marketing ... Nordics and the US , Photocure to commercialise ... Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on ... of a new commercial strategy for Hexvix, its flagship product ...
    ... Luminex Corporation (NASDAQ: LMNX ), today ... its annual European multiplexing technology symposium, September 28-29, 2011, ... feature scientific sessions, workshops, discussion groups, exhibitions and networking ... who are performing groundbreaking work in clinical diagnostics and ...
    Cached Medicine Technology:Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 2Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 3Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 4Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 5Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 6Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 7Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 8Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 2Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 3Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 4
    (Date:4/17/2014)... Meaningful long-term survival is possible for selected patients ... treated with cytoreductive surgery with Hyperthermic IntraPeritoneal Chemotherapy, ... physicians at Wake Forest Baptist Medical Center. , ... experience with cytoreductive surgery and HIPEC, said lead ... 20 years, worth of patient data shows that ...
    (Date:4/17/2014)... Canadians surveyed said they would participate in public health ... genetic conditions, only 80 per cent said they would ... their newborns, genomes.,Most newborns in North America have a ... of life in which a tiny amount of blood ... five to 54 conditions, depending on the state or ...
    (Date:4/17/2014)... have called for more research to be carried ... in sub-Saharan Africa. In a paper in ... Stothard, working with colleagues in the department of ... in Cleveland Ohio, University of Cambridge and the ... the joint burden of HIV/AIDS and schistosomiasis of ...
    (Date:4/16/2014)... Texas (April 16, 2014) A team that includes scientists ... Health Science Center at San Antonio, Johns Hopkins University and ... helps a common fungus to infect the body. , The ... rashes and oral thrush, and is the most common fungal ...
    (Date:4/15/2014)... Handling frozen fish caused nearly half of all ... the injuries on freezer-longliner vessels operating off the coast ... , Many of those injuries and others aboard the ... right interventions, and the research methods used in the ...
    Breaking Medicine News(10 mins):Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Changes in processing, handling could reduce commercial fishing injuries 2
    ... Diego – Obesity is back in the news with one ... Cancer. People who are obese carry an enhanced risk of ... California, San Diego have unearthed the link between obesity and ... the obese secrete a hormone called leptin, which induces growth ...
    ... proportions”, a study finding which says that hormone replacement therapy ... of heart disease. , The study published in ... replacement therapy or HRT, taken by women in their 50’s ... attacks and other such conditions. , This finding ...
    ... a possible herbal cure for urinary track// infection (UTI). ... Center found that the herb called forskalin or ... UTI as well as help antibiotics kill 90 percent of ... and Urologic Diseases Information Clearinghouse (NKUDIC) says urinary tract infections ...
    ... will soon start an integrated trauma care facility to ... //to patients on way to a hospital from an ... of Physicians of Indian Origin (AAPI), the emergency medical ... fully equipped ambulances within minutes of an accident., ...
    ... of developing colon cancer, the third most common form of ... body of obese people produce leptin - a hormone that ... a person has, the more leptin will be in their ... Surgery. ,A colon cancer patient suffers from cancerous ...
    ... US-based ImClone Systems and Bristol-Myers Squibb have announced that ... with platinum-based //chemotherapy have increased survival chances among cancer ... the head and neck (SCCHN). ,Worldwide SCCHN ... head and neck, and approximately two-thirds of all patients ...
    Cached Medicine News:Health News:Hormone Replacement Therapy- Not A Fallen Angel 2Health News:Ancient Indian Herb May Prove Cure For Recurrent UTI 2Health News:Integrated Trauma Care Facility in Mumbai 2Health News:Integrated Trauma Care Facility in Mumbai 3Health News:A New Erbitux Combo Shows Promise in treatment 2
    Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
    Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
    Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
    ... precise episcleral, intrascleral, and intraocular hemostasis ... Rf diathermy delivers targeted coagulation with ... Eraser instruments, forceps and cables. This ... a high level of Wet-Field safety ...
    Medicine Products: